Global Bioprocess Validation Market Research Report 2022-2024 and 2030: Biosimilars Gain from Patent Expiry of Major Drugs, Driving Gains for Bioprocess Validation

Global Bioprocess Validation Market Research Report 2022-2024 and 2030: Biosimilars Gain from Patent Expiry of Major Drugs, Driving Gains for Bioprocess Validation

DUBLIN, March 1, 2024 /PRNewswire/ — The “Bioprocess Validation – Global Strategic Business Report” report has been added to  ResearchAndMarkets.com’s offering.

Global Bioprocess Validation Market to Reach $622.6 Million by 2030

The global market for Bioprocess Validation estimated at US$253.5 Million in the year 2022, is projected to reach a revised size of US$622.6 Million by 2030, growing at a CAGR of 11.9% over the analysis period 2022-2030.

Extractables / Leachables Testing Services, one of the segments analyzed in the report, is projected to record 13.1% CAGR and reach US$255.6 Million by the end of the analysis period. Growth in the Integrity Testing Services segment is estimated at 12% CAGR for the next 8-year period.

The pandemic significantly impacted the bioprocess validation market, altering its trajectory and dynamics. Bioprocess validation, a critical aspect of ensuring product quality and regulatory compliance in biopharmaceutical manufacturing, encompasses various validation processes. The global market outlook for bioprocess validation remains optimistic, with extractables/leachables testing services emerging as the largest segment.

Developed regions currently lead the market, but developing economies show promise for future growth. Competition in the bioprocess validation market is fierce, with key competitors vying for market share, as indicated by the percentage market share breakdown in 2023. Market players worldwide exhibit varying degrees of market presence, categorized as strong, active, niche, or trivial. Recent market activity reflects ongoing developments and strategic maneuvers within the industry. 

The U.S. Market is Estimated at $95 Million, While China is Forecast to Grow at 17.3% CAGR

The Bioprocess Validation market in the U.S. is estimated at US$95 Million in the year 2022. China, the world’s second largest economy, is forecast to reach a projected market size of US$80.8 Million by the year 2030 trailing a CAGR of 17.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 10.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.5% CAGR.

MARKET OVERVIEW

Pandemic Impact on Bioprocess Validation MarketAn Introduction to Bioprocess ValidationTypes of Process ValidationGlobal Market OutlookExtractables/Leachables Testing Services: The Largest SegmentDeveloped Regions Lead, Developing Economies Promise Future GrowthCompetitionBioprocess Validation – Global Key Competitors Percentage Market Share in 2023 (E)Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)Recent Market Activity

MARKET TRENDS & DRIVERS

Rapid Growth in Biopharmaceutical Production and Need to Prevent Product Contamination Necessitate Validation ServicesGlobal Biopharmaceuticals Market in US$ Billion for the Years 2022, 2024, 2026 and 2028Increasing Pharma & Biotech Investments into Drug Development Activities Fuel Need for Bioprocess ValidationPharmaceutical R&D Spending Worldwide (USD Billion) for 2015-2025Rise of Pharma Contract Manufacturing Present Growth Opportunities for Bioprocess Validation Outsourcing to Emerging MarketsGlobal Pharmaceutical Contract Manufacturing Market by Geographic Region for 2021 and 2027Biosimilars Gain from Patent Expiry of Major Drugs, Driving Gains for Bioprocess Validation MarketStrict Safety & Quality Regulations and Compliance with cGMP for Biopharmaceuticals Support Market GrowthBioprocessing 4.0: Implications for Bioprocess ValidationValidation 4.0: Essential for Sciences Industry Progresses towards Digital-First IndustryGrowing Prominence of Paperless Validation in Pharma, Biotech & Medical Devices IndustriesBioprocess Innovations Direct Focus onto Effective & Clear ValidationsDigital Twins to Support Bioprocess Validation Market GrowthAI-Enabled System-Led Transformations in Biomanufacturing & Bioprocess ValidationArtificial Intelligence and Continuous ValidationSingle-Use Disposable Technologies Gain AttentionBioprocess Data: Critical for Improving Efficiency of Pharma Developments & Manufacturing OperationsAdvancing Process Analytical Technologies Necessitates ValidationProcess Validation for Viral Vectors: What are the Key Challenges?Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market GrowthFatalities by Heart Conditions – Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and OthersChallenges Confronting Bioprocess Validation

FOCUS ON SELECT PLAYERS (Total 50 Featured)

Almac GroupBangalore Biotech Labs Pvt Ltd (Biozeen)DOC S.r.lEurofins Scientific SEHangzhou Cobetter Filtration Equipment Co. Ltd.Lonza Group AGMeissner Filtration Products, Inc.Merck KGaAPall Corporation, a subsidiary of Danaher CorporationPorvair PlcSartorius AGSGS S.A.Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/1etkft

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/global-bioprocess-validation-market-research-report-2022-2024-and-2030-biosimilars-gain-from-patent-expiry-of-major-drugs-driving-gains-for-bioprocess-validation-302077456.html

SOURCE Research and Markets